Clinical trial
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using…
NCT00367484 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00367484 |
|---|---|
| Title | Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis |
| Official title | Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing Remitting Multiple Sclerosis |
| Intervention type | Biological |
| Interventions | Rebif® (clone 484-39) |
| Enrollment | 460 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Aug 23, 2006 |
| Last update posted | Feb 27, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: